Denosumab Shows Benefits in Multiple Myeloma Bone Disease Denosumab Shows Benefits in Multiple Myeloma Bone Disease
In a head-to-head comparison with zoledronic acid, denosumab was noninferior, with prolonged time to a first skeletal event and a reduced risk for renal events.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news